Who
Michael Grissinger
Director
Company insider
Files Form 4 as: Director, Lipocine; Director, Adicet Bio; Director, Aprea Therapeutics; Director, Akari Therapeutics.
In numbers
- Trades disclosed
- 21
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 5 Nov 2018
- Last trade
- 3 Aug 2026
- Last filed
- 7 Aug 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 7 Aug 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $4,2202,000 at $2.11 | filing |
| 3 Aug 2026filed 7 Aug 2026 | LPCN Lipocineoption or derivative · Biotechnology | SEC FORM 4 Code A | $4,2202,000 at $2.11 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 21 Jun 2026filed 23 Jun 2026 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —4,200 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,555 at $0.00 | filing |
| 16 Jun 2026filed 17 Jun 2026 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —3,135 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,045 at $0.00 | filing |
| 17 Apr 2025filed 21 Apr 2025 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —70,200 at $0.00 | filing |
| 28 Jun 2024filed 2 Jul 2024 | AKTX Akari Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000,000 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,185 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —1,045 at $0.00 | filing |
| 23 Aug 2023filed 24 Aug 2023 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 23 Aug 2023filed 24 Aug 2023 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —500 at $0.00 | filing |
| 28 Jul 2022filed 1 Aug 2022 | APRE Aprea Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,575 at $0.00 | filing |
| 28 Jul 2022filed 1 Aug 2022 | APRE Aprea TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,995 at $0.00 | filing |
| 3 Jun 2020filed 5 Jun 2020 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —14,414 at $0.00 | filing |
| 8 May 2019filed 9 May 2019 | ACET Adicet Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —14,414 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.